Soft Tissue Sarcoma

More than 50 distinct cancer types fall under the soft tissue sarcoma umbrella, each originating in muscle, fat, blood vessels, nerves, or connective tissue instead of bone. Most start small and painless, which is often why they go unnoticed until they've grown enough to press against nearby structures. Knowing exactly which sarcoma diagnosis a veteran is dealing with matters just as much as the diagnosis itself, and Asbestos Ships helps sort out where a specific diagnosis stands with a VA claim.

Soft tissue sarcoma types recognized by the VA

The VA's Agent Orange presumption recognizes a specific set of soft tissue sarcoma types, and the cancer generally needs to originate in muscle, fat, blood vessels, lymph vessels, or connective tissue to fit the VA's definition. Several of the more commonly diagnosed types are listed below.

• Fibrosarcoma, liposarcoma, and leiomyosarcoma
• Rhabdomyosarcoma and angiosarcoma
• Synovial sarcoma and malignant schwannoma
• Epithelioid sarcoma, clear cell sarcoma, and extraskeletal Ewing's sarcoma

These types, along with several other named sarcomas under federal regulation, form the basis for a presumptive claim once paired with qualifying service.

Soft tissue sarcoma and Agent Orange

Once a veteran has a diagnosis matching one of the covered sarcoma types and meets the required exposure and service criteria, the VA treats the connection to Agent Orange as already established. There's no need to separately prove the cancer began during service or was caused or aggravated by military duty, which is different from how a non-presumptive condition gets evaluated.

This distinction matters because it shifts the burden away from the veteran. Rather than gathering medical opinions to argue for a connection, the focus becomes confirming the diagnosis and documenting the qualifying service itself.

Where this presumption comes from

Herbicide exposure and soft tissue sarcoma have one of the more thoroughly reviewed relationships in the Agent Orange research. The National Academies concluded in its 2018 update that the evidence supporting this connection met its highest bar, sufficient evidence of an association, placing sarcoma alongside a small group of diseases with that same strong classification.

Much of that evidence traces back further than TCDD alone. Case-control studies involving workers exposed to phenoxy herbicides and chlorophenols identified elevated sarcoma rates well before dioxin contamination became the central focus of later Agent Orange research, giving the overall connection a broader scientific foundation than a single chemical pathway would provide.

Where the exposure presumption applies

Matching a specific location to its qualifying dates is what determines whether the VA presumes herbicide exposure automatically, rather than asking a veteran to prove it happened. Each location below comes with its own separate timeframe.

• Vietnam, on land or as a Blue Water Navy sailor within its territorial waters, from January 9, 1962, through May 7, 1975
• Thailand, at any U.S. or Royal Thai military base, from January 9, 1962, through June 30, 1976
• The Korean DMZ, for specific qualifying units, from September 1, 1967, through August 31, 1971
• Laos, from December 1, 1965, through September 30, 1969
• Cambodia, specifically at Mimot or Krek in Kampong Cham Province, from April 16 through April 30, 1969
• Guam or American Samoa, including territorial waters, from January 9, 1962, through July 31, 1980
• Johnston Atoll, or service aboard a ship that called there, from January 1, 1972, through September 30, 1977

Once service falls within one of these windows, a diagnosis matching one of the covered sarcoma types generally satisfies what the VA looks for.

How the VA assigns a rating

Sarcomas originating in muscle, fat, or fibrous connective tissue are evaluated under Diagnostic Code 5329, which calls for a 100 percent rating throughout active disease and treatment. Six months past the end of treatment, the VA schedules a required exam to determine what rating applies going forward.

Provided that the exam shows no recurrence, the rating adjusts to reflect any lasting functional impairment rather than staying at the maximum level. For 2026, that full rating pays $3,938.58 monthly for a veteran with no dependents, increasing to $4,158.17 with a spouse and no other dependents, with none of it subject to tax.

Compensation for surviving family members

When a covered soft tissue sarcoma leads to a veteran's death and Agent Orange exposure is part of the picture, surviving family members can pursue their own DIC claim. This runs independently of whatever the veteran received in disability payments during their lifetime.

Eligibility doesn't hinge on the veteran having filed a claim before they passed. The family's case instead rests on connecting the death itself to a qualifying diagnosis and confirmed herbicide exposure.

Getting support from Asbestos Ships

Matching a specific pathology report against a list of named sarcoma types isn't something most families are prepared to do on their own. This is precisely the kind of detail work Asbestos Ships helps veterans and their loved ones sort through.

• Referrals to VA-accredited representatives who take these claims without upfront fees
• Direct answers on whether a diagnosed sarcoma type falls within the presumption
• Help locating your nearest VA regional office or medical center
• Connections to legal resources for compensation beyond the VA system

A rare cancer with a technical name shouldn't leave a veteran or their family guessing about next steps. Getting a clear answer on whether a diagnosis fits the VA's framework is often what moves a stalled claim forward. Connect with Asbestos Ships, and our team will walk through your diagnosis and service record to map out your options.